NASDAQ:SELB - Selecta Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.20
  • Forecasted Upside: 87.50 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$3.84
▲ +0.18 (4.92%)
1 month | 3 months | 12 months
Get New Selecta Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SELB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SELB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.20
▲ +87.50% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $7.20, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 87.50% upside from the last price of $3.84.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Selecta Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/18/2021William BlairUpgradeMarket Perform ➝ OutperformMedium
i
Rating by R. Prasad at William Blair
3/12/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by R. Prasad at William Blair
1/26/2021MizuhoUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
i
1/7/2021Canaccord GenuityReiterated RatingBuy$13.00N/A
i
1/7/2021HC WainwrightReiterated RatingBuy$6.00N/A
i
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by K. Kluska at Cantor Fitzgerald
10/5/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $6.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/1/2020MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $2.50High
i
Rating by Difei Yang at Mizuho
10/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by R. Prasad at William Blair
8/7/2020MizuhoReiterated RatingBuy$7.00Medium
i
Rating by Difei Yang at Mizuho
8/7/2020Canaccord GenuityReiterated RatingBuyMedium
i
7/6/2020Canaccord GenuityReiterated RatingBuyLow
i
6/18/2020HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/18/2020Stifel NicolausReiterated RatingHoldHigh
i
Rating by Derek Archila at Stifel Nicolaus
6/18/2020Needham & Company LLCReiterated RatingBuy$5.00Medium
i
Rating by Chad Messer at Needham & Company LLC
6/16/2020Canaccord GenuityReiterated RatingBuy$13.00High
i
6/12/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
Rating by Chad Messer at Needham & Company LLC
6/12/2020Stifel NicolausDowngradeBuy ➝ Hold$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
6/12/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $10.00High
i
Rating by R. Selvaraju at HC Wainwright
6/10/2020MizuhoReiterated RatingBuy$7.00Low
i
5/7/2020Stifel NicolausReiterated RatingBuy$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
5/7/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
5/7/2020William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
4/28/2020HC WainwrightInitiated CoverageBuy$8.00High
i
Rating by R. Selvaraju at HC Wainwright
3/13/2020Canaccord GenuityReiterated RatingBuyHigh
i
3/12/2020Stifel NicolausReiterated RatingBuy$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
2/18/2020MizuhoReiterated RatingBuy$4.00 ➝ $7.00High
i
1/29/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00Low
i
Rating by E. Merle at Cantor Fitzgerald
1/21/2020William BlairInitiated CoverageOutperformHigh
i
Rating by R. Prasad at William Blair
12/19/2019MizuhoReiterated RatingBuy$4.00Low
i
Rating by Difei Yang at Mizuho
12/19/2019Stifel NicolausReiterated RatingBuyHigh
i
11/8/2019Needham & Company LLCReiterated RatingBuy$9.00Low
i
11/8/2019Stifel NicolausReiterated RatingBuy$6.00Low
i
8/11/2019MizuhoReiterated RatingBuy$4.00Medium
i
8/9/2019Stifel NicolausReiterated RatingBuy$6.00Low
i
5/10/2019MizuhoReiterated RatingBuy$4.00Low
i
3/18/2019Canaccord GenuityLower Price TargetReduce ➝ Buy$25.00 ➝ $13.00High
i
3/15/2019Stifel NicolausReiterated RatingBuy$7.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
2/5/2019Stifel NicolausSet Price TargetBuy$7.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
2/4/2019MizuhoLower Price TargetBuy$4.00Low
i
1/28/2019Needham & Company LLCLower Price TargetBuy$12.00Low
i
11/9/2018UBS GroupSet Price TargetHold$6.00Medium
i
Rating by Carter Gould at UBS Group AG
11/5/2018MizuhoReiterated RatingBuy$30.00Medium
i
10/23/2018Janney Montgomery ScottReiterated RatingBuyHigh
i
Rating by Yun Zhong at Janney Montgomery Scott
10/23/2018Stifel NicolausReiterated RatingBuyMedium
i
Rating by Derek Archila at Stifel Nicolaus
10/17/2018MizuhoReiterated RatingBuy$30.00High
i
9/14/2018Stifel NicolausInitiated CoverageBuy$24.00Low
i
8/9/2018MizuhoReiterated RatingBuy$30.00High
i
7/11/2018Canaccord GenuityReiterated RatingBuy$40.00High
i
6/28/2018Canaccord GenuityReiterated RatingBuy$40.00High
i
6/27/2018Janney Montgomery ScottInitiated CoverageBuy$33.00Low
i
5/23/2018Canaccord GenuityBoost Price TargetBuy$30.00 ➝ $40.00Low
i
4/11/2018MizuhoReiterated RatingBuy$30.00High
i
2/26/2018MizuhoInitiated CoverageBuy$30.00High
i
1/18/2018Canaccord GenuityReiterated RatingBuy$30.00Low
i
Rating by John Newman at Canaccord Genuity
1/3/2018Canaccord GenuityReiterated RatingBuyHigh
i
Rating by John Newman at Canaccord Genuity
11/9/2017UBS GroupDowngradeBuy ➝ NeutralN/A
i
11/7/2017Canaccord GenuityReiterated RatingBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
10/12/2017Canaccord GenuityBoost Price TargetBuy$25.00 ➝ $30.00N/A
i
Rating by John Newman at Canaccord Genuity
8/11/2017Canaccord GenuitySet Price TargetBuy$25.00Low
i
Rating by John Newman at Canaccord Genuity
7/26/2017Canaccord GenuitySet Price TargetBuy$25.00High
i
Rating by John Newman at Canaccord Genuity
5/13/2017Canaccord GenuitySet Price TargetBuy$25.00Low
i
Rating by John Newman at Canaccord Genuity
3/30/2017UBS GroupReiterated RatingBuy ➝ Buy$26.00N/A
i
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00High
i
12/9/2016UBS GroupReiterated RatingBuy$19.00 ➝ $29.00N/A
i
Rating by Jeffrey Hung at UBS Group AG
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 ➝ $32.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
12/6/2016Canaccord GenuitySet Price TargetBuy$25.00N/A
i
Rating by John Newman at Canaccord Genuity
11/12/2016Canaccord GenuitySet Price TargetBuy$25.00N/A
i
Rating by John Newman at Canaccord Genuity
7/18/2016Needham & Company LLCInitiated CoverageBuy$28.00N/A
i
7/18/2016Canaccord GenuityInitiated CoverageBuy$20.00N/A
i
7/18/2016UBS GroupInitiated CoverageBuy$19.00N/A
i
7/18/2016Stifel NicolausInitiated CoverageBuy$23.00N/A
i
(Data available from 4/22/2016 forward)
Selecta Biosciences logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $3.84
$3.58
$3.86

50 Day Range

MA: $4.18
$3.66
$4.68

52 Week Range

Now: $3.84
$1.47
$5.70

Volume

460,048 shs

Average Volume

1,692,151 shs

Market Capitalization

$431.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Selecta Biosciences?

The following Wall Street analysts have issued reports on Selecta Biosciences in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, Mizuho, Needham & Company LLC, Stifel Nicolaus, William Blair, and Zacks Investment Research.
View the latest analyst ratings for SELB.

What is the current price target for Selecta Biosciences?

5 Wall Street analysts have set twelve-month price targets for Selecta Biosciences in the last year. Their average twelve-month price target is $7.20, suggesting a possible upside of 87.5%. Canaccord Genuity has the highest price target set, predicting SELB will reach $13.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.00 for Selecta Biosciences in the next year.
View the latest price targets for SELB.

What is the current consensus analyst rating for Selecta Biosciences?

Selecta Biosciences currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SELB will outperform the market and that investors should add to their positions of Selecta Biosciences.
View the latest ratings for SELB.

What other companies compete with Selecta Biosciences?

How do I contact Selecta Biosciences' investor relations team?

Selecta Biosciences' physical mailing address is 65 Grove Street, Watertown MA, 02472. The company's listed phone number is 617-923-1400 and its investor relations email address is [email protected] The official website for Selecta Biosciences is selectabio.com.